A carregar...
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369644/ https://ncbi.nlm.nih.gov/pubmed/32764980 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S259308 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|